We’re excited to announce that we’ve added 12 new companies to the Psychedelic Invest Index – making us fully up to date on all the recent listings.

The Psychedelic Invest Index, the first ever to track the entire public sector of the psychedelic market, now features:

  • Field Trip Health: FTRP:CSE
  • Compass Pathways: CMPS:NASDAQ
  • Mindcure: MCUR:CSE
  • Global Trac Solutions: PSYC:OTC
  • HAVN Life Sciences: HAVN:CSE
  • Pharmadrug: BUZZ:CSE
  • Aion Therapeutic: AION:CSE
  • Core One Labs: COOL:CSE
  • Nova Mentis Life Science Corp: NOVA:CSE
  • Greenstar Biosciences: GSTR:CSE
  • Silo Pharma: SILO:OTC
  • Pharmather Inc: PHRM:CSE

The recent additions have been made effective, or otherwise backdated, to October 1, 2020.

In total, the index is now comprised of 34 constituents – an increase of 54%. This increase reflects just how quickly the psychedelic public sector is growing. In the past 30 days alone, we’ve already seen 4 psychedelic companies join the public markets.

That said, total market capitalization displays just how nascent the space remains. Out of all 34 publicly traded companies, only 4 have a market cap above $100 million, and only one, Compass Pathways (CMPS), has a market cap above $1 billion.

Since the rebasing on October 1, 2020, the Psychedelic Invest Index is up 16.62% with an average volume of $54.24 million.

The Psychedelic Invest Index aims to aid investors looking to gain exposure and transparency to the burgeoning psychedelic market. Look out for further updates and more deep dive analysis in the month ahead.